{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:41:38Z","timestamp":1772743298763,"version":"3.50.1"},"reference-count":10,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J of Pharm Policy and Pract"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SARS-CoV2 is dramatically impacting the global population. Worldwide, pharmacists are changing their roles and being increasingly recognized for their role as essential service providers. This commentary provides some examples collected from Asia, Europe, the Americas and Africa, ranging from essential services to meet human rights basic needs, extended generalist services developed to ensure continuity of care and supply of essential medicines to the development of differentiated extended responsibilities in emergency care. All examples were collected using a network of pharmacists from 27 countries, representing various areas of pharmacy practice, education and research and outreaching to include patient advocates. Selected services illustrate good practice, capability to adapt and contribution to universal health coverage. Above all, it demonstrates the commitment and innovation of the pharmaceutical workforce in the fight against COVID-19.<\/jats:p>","DOI":"10.1186\/s40545-020-00216-4","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T12:02:43Z","timestamp":1590408163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacists reinventing their roles to effectively respond to COVID-19: a global report from the international pharmacists for anticoagulation care taskforce (iPACT)"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-2514","authenticated-orcid":false,"given":"Filipa","family":"Alves da Costa","sequence":"first","affiliation":[]},{"given":"Vivian","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Silvana Nair","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Maria Dolores","family":"Murillo","sequence":"additional","affiliation":[]},{"given":"Tom","family":"Menge","sequence":"additional","affiliation":[]},{"given":"Sotiris","family":"Antoniou","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"216_CR1","unstructured":"International Pharmaceutical Federation. Coronavirus\/COVID-19 preparedness. Available on: https:\/\/www.fip.org\/coronavirus. Accessed 17 Apr 2020."},{"key":"216_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40545-020-00210-w","volume":"13","author":"N Bukhari","year":"2020","unstructured":"Bukhari N, Rasheed H, Nayyer B, Babar Z. Pharmacists at the frontline beating the COVID-19 pandemic. J Pharmaceut Policy Pract. 2020;13:8.","journal-title":"J Pharmaceut Policy Pract"},{"key":"216_CR3","unstructured":"Center for Disease Control and Prevention. Considerations for Pharmacies during the COVID-19 Pandemic. Available on: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/pharmacies.html. Accessed 19 Apr 2020."},{"key":"216_CR4","unstructured":"General Pharmaceutical Council. Latest updates on COVID-19 (coronav\u00edrus). Available on: https:\/\/www.pharmacyregulation.org\/contact-us\/coronavirus-latest-updates. Accessed 17 Apr 2020."},{"key":"216_CR5","unstructured":"General Council of Official Colleges of Pharmacists of Spain, COVID-19 updates. Published in Portalfarma, The number of infected professionals increases 66% and 65 pharmacies remain shut. \u201cAumenta un 66% el n\u00famero de profesionales infectados y 65 farmacias permanecen cerradas\u201d [available in Spanish], available on: https:\/\/www.portalfarma.com\/Profesionales\/consejoinforma\/Paginas\/2020-registro-abril-afectados-coronavirus-farmacias-comunitarias.aspx. Accessed 10 Apr 2020."},{"key":"216_CR6","volume-title":"Propuesta para la dispensaci\u00f3n y entrega de medicamentos y prodcutos sanit\u00e1rios en el domic\u00edlio del paciente desde la farm\u00e1cia comunit\u00e1ria durante el estado de alarma por COVID-19. Madrid: Sociedad Espa\u00f1ola de Farmacia Familiar y Comunit\u00e1ria (SEFAC)","author":"VJ Baixauli","year":"2020","unstructured":"Baixauli VJ, Satu\u00e9 E, Murillo M\u00aa D, Molinero A, G\u00f3mez JC, Estrada G. Propuesta para la dispensaci\u00f3n y entrega de medicamentos y prodcutos sanit\u00e1rios en el domic\u00edlio del paciente desde la farm\u00e1cia comunit\u00e1ria durante el estado de alarma por COVID-19. Madrid: Sociedad Espa\u00f1ola de Farmacia Familiar y Comunit\u00e1ria (SEFAC); 2020. [available in Spanish]. Proposal for community pharmacies to dispense and deliver medications and sanitary products at patients\u2019 homes during the emergency state by COVID-19."},{"key":"216_CR7","unstructured":"Sociedad Espa\u00f1ola de Farmacia Familiar y Comunit\u00e1ria (SEFAC). Available on: https:\/\/www.sefac.org\/sesion-online-covid-19-y-enfermedades-respiratorias-cronicas. Accessed 10 Apr 2020."},{"key":"216_CR8","unstructured":"Circular Normativa n\u00b0 005\/CD\/550.20.001. Issued 07\/04\/2020. Guidance on access to hospital only medication through community pharmacies in the context of COVID-19 pandemic [available in Portuguese]. Available on: https:\/\/www.infarmed.pt\/web\/infarmed\/infarmed\/-\/journal_content\/56\/15786\/3624277. Accessed 10 Apr 2020."},{"key":"216_CR9","unstructured":"Portaria n\u00b0 90-A\/2020. Issued 09\/04\/2020. Exceptional and temporary measures for electronic prescribing of medicines during COVID-19 pandemic [available in Portuguese]. Available on: https:\/\/dre.pt\/pesquisa\/-\/search\/131338887\/details\/maximized. Accessed 10 Apr 2020."},{"key":"216_CR10","unstructured":"ANVISA warning 20280. Available on: http:\/\/www.in.gov.br\/en\/web\/dou\/-\/resolucao-rdc-n-357-de-24-de-marco-de-2020-249501721. Accessed 10 April 2020."}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40545-020-00216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40545-020-00216-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40545-020-00216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T10:53:12Z","timestamp":1704279192000},"score":1,"resource":{"primary":{"URL":"https:\/\/joppp.biomedcentral.com\/articles\/10.1186\/s40545-020-00216-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1186\/s40545-020-00216-4","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"26 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are members of iPACT, which has been funded by DRM-Foundation. There was no funding for the development of this commentary. The views expressed represent solely those involved in writing the commentary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}